Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0TTWQU |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | anti-MSR1 |
|||||
| Organization | REGENERON PHARMACEUTICALS, INC. |
|||||
| Synonyms |
anti-MSR1
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Protein MANNAN SYNTHESIS-RELATED 1 (MSR1) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
H1H21234N-N297Q-LP9 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.414 nM
|
Positive MSR1 expression (MSR1+++/++) | ||
| Method Description |
Anti-MSR1-LXR Agonist Conjugate Activity in Differentiated THP-4/LXR-Luc cells
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP-1/LXR-Luc cells | CVCL_5115 | ||
H1H21234N-N297Q-LP7 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.56 nM
|
Positive MSR1 expression (MSR1+++/++) | ||
| Method Description |
Anti-MSR1-LXR Agonist Conjugate Activity in Differentiated THP-4/LXR-Luc cells
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP-1/LXR-Luc cells | CVCL_5115 | ||
H1H21234N-N297Q-LP8 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.619 nM
|
Positive MSR1 expression (MSR1+++/++) | ||
| Method Description |
Anti-MSR1-LXR Agonist Conjugate Activity in Differentiated THP-4/LXR-Luc cells
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP-1/LXR-Luc cells | CVCL_5115 | ||
H1H21234N-N297Q-LP6 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.685 nM
|
Positive MSR1 expression (MSR1+++/++) | ||
| Method Description |
Anti-MSR1-LXR Agonist Conjugate Activity in Differentiated THP-4/LXR-Luc cells
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP-1/LXR-Luc cells | CVCL_5115 | ||
H1H21234N-N297Q-LP1 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.738 nM
|
Positive MSR1 expression (MSR1+++/++) | ||
| Method Description |
Anti-MSR1-LXR Agonist Conjugate Activity in Differentiated THP-1/LXR-Luc cells
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP-1/LXR-Luc cells | CVCL_5115 | ||
H1H21234N-N297Q-LP2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.868 nM
|
Positive MSR1 expression (MSR1+++/++) | ||
| Method Description |
Anti-MSR1-LXR Agonist Conjugate Activity in Differentiated THP-4/LXR-Luc cells
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP-1/LXR-Luc cells | CVCL_5115 | ||
H1H21234N-N297Q-LP4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.923 nM
|
Positive MSR1 expression (MSR1+++/++) | ||
| Method Description |
Anti-MSR1-LXR Agonist Conjugate Activity in Differentiated THP-2/LXR-Luc cells
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP-1/LXR-Luc cells | CVCL_5115 | ||
H1H21234N-N297Q-LP10 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.96 nM
|
Positive MSR1 expression (MSR1+++/++) | ||
| Method Description |
Anti-MSR1-LXR Agonist Conjugate Activity in Differentiated THP-4/LXR-Luc cells
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP-1/LXR-Luc cells | CVCL_5115 | ||
H1H21234N-N297Q-LP11 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.978 nM
|
Positive MSR1 expression (MSR1+++/++) | ||
| Method Description |
Anti-MSR1-LXR Agonist Conjugate Activity in Differentiated THP-4/LXR-Luc cells
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP-1/LXR-Luc cells | CVCL_5115 | ||
H1H21234N-N297Q-LP5 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.2 nM
|
Positive MSR1 expression (MSR1+++/++) | ||
| Method Description |
Anti-MSR1-LXR Agonist Conjugate Activity in Differentiated THP-3/LXR-Luc cells
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP-1/LXR-Luc cells | CVCL_5115 | ||
H1H21234N-N297Q-LP12 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.3 nM
|
Positive MSR1 expression (MSR1+++/++) | ||
| Method Description |
Anti-MSR1-LXR Agonist Conjugate Activity in Differentiated THP-4/LXR-Luc cells
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP-1/LXR-Luc cells | CVCL_5115 | ||
References